CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
CG Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$59.96+0.11 (+0.18%)
Close on Oct 19, 2026
- Market cap
- $5.29B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$18.50 (+44.62%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
CG Oncology, Inc. grew revenue 1030.3% to $6.23M over the twelve months to Jun 30, 2026. Free cash flow was -$179.34M.
Revenue
$6.23M
+1030.3% vs. a year earlier
Operating income
-$252.62M
TTM Q2 2026
Free cash flow
-$179.34M
TTM Q2 2026
EPS, diluted
-$2.70
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $5.29B
- P/E ratio
- –
- Price to sales
- 849.14
- Price to book
- 5.14
- Dividend yield
- –
- Free cash flow yield
- -3.39%
Fundamentals
- Revenue
- $6.23M
- Net income
- -$224.38M
- EPS, diluted
- -$2.70
- Free cash flow
- -$179.34M
- Book value per share
- $11.67
- Diluted shares
- 88M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
$6.23M+1030.3% YoY
Operating income
-$252.62M
Net income
-$224.38M
EPS, diluted
-$2.70
Free cash flow
-$179.34M
Reported periodTrailing twelve months